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Abstract
Treatment of osteoporotic patients with bisphosphonates (BPs) preserves bone mass and microarchitecture. The high
prescription rate of the drugs brings about increases in the numbers of fractures and bone defects requiring surgical
interventions in these patients. Currently, critical-size defects are filled with biomaterials and healing is supported with
bone morphogenetic proteins (BMP). It is hypothesized that BPs interfere with biomaterial turnover during BMP-
supported repair of defects filled with b-tricalcium phosphate (bTCP) ceramics. To test this hypothesis, retired bree-
der rats were ovariectomized (OVX). After 8 weeks, treatment with alendronate (ALN) commenced. Five weeks later, 6
mm diaphyseal femoral defects were applied and stabilized with locking plates. bTCP cylinders loaded with 1 mg and 10 mg
BMP2, 10 mg L51P, an inhibitor of BMP antagonists and 1 mg BMP2/10 mg L51P were fitted into the defects. Femora were
collected 16 weeks post-implantation. In groups receiving calcium phosphate implants loaded with 10 mg BMP2 and 1 mg
BMP2/10 mg L51P, the volume of bone was increased and bTCP was decreased compared to groups receiving implants
with 1 mg BMP2 and 10 mg L51P. Treatment of animals with ALN caused a decrease in bTCP turnover. The results
corroborate the synergistic effects of BMP2 and L51P on bone augmentation. Administration of ALN caused a reduction
in implant turnover, demonstrating the dependence of bTCP removal on osteoclast activity, rather than on chemical
solubility. Based on these data, it is suggested that in patients treated with BPs, healing of biomaterial-filled bone defects
may be impaired because of the failure to remove the implant and its replacement by authentic bone.
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Introduction
Each year, worldwide more than 8.9 million osteoporosis-
related fractures are counted.1 Loss of bone mass and dete-
rioration of microarchitecture in post-menopausal women
are the primary causes for the increase in fracture risk.
Bisphosphonates (BPs) are widely considered as the drugs
of choice for the prevention of bone loss in post-
menopausal osteoporosis. BP bind to calcium phosphate
(CaP) minerals with high and prolonged affinity.2,3 Upon
cellular uptake, the drugs block osteoclastic bone resorp-
tion, resulting in stabilization of bone mass and preserva-
tion of structure.2,3 Administration of alendronate (ALN),
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the most frequently prescribed BP, results in a reduction of
hip and vertebral fractures.4–9 Because BPs are widely used
and elderly patients with osteoporosis are prone to frac-
tures, there has been an interest to understand the effects
of BP on bone repair. In vivo studies on fracture healing in
rodents reported an increase in callus size and a delay in
bone remodelling upon treatment with ALN.10–12 Further-
more, in a number of surgical interventions such as spinal
fusion or the repair of large bone defects, bone morphoge-
netic proteins (BMP), such as BMP2 and BMP7, and CaP-
based biomaterials need to be used. To achieve clinical
efficacy, however, these growth factors are administered
in supraphysiological dosages.13 This may be caused, at
least in part, by a reduction in bioavailability of the BMP,
since the growth factors induce the expression of antago-
nists at the repair site.14,15 Indeed, an increase in the expres-
sion of BMP antagonists was demonstrated during fracture
healing and distraction osteogenesis.16–18 Furthermore,
biomaterials need to be removed in a timely manner to
allow for efficient replacement by authentic bone. To this
purpose, it is essential to ensure that implant removal is
governed by cellular processes rather than solely chemical
dissolution. To improve the bioavailability of BMP2, L51P,
an in vitro engineered BMP2 variant with a leucine to pro-
line substitution at amino acid 51, was developed. This
modified protein does not activate BMP type I receptor but
has affinity for BMP type II receptors and the BMP antago-
nists noggin, gremlin and others.19 After demonstrating that
L51P restored BMP2-mediated osteoblast differentiation
by inhibiting noggin in vitro,20 we and others reported that
L51P increased the biological efficacy of BMP2 and that
the amount of BMP2 required to induce clinically relevant
bone formation in a femoral critical-size segmental defect
rat model21 or in a calvaria defect model22,23 could be
reduced. Since BP were shown to stabilize bone mass and
to maintain bone microarchitecture by reducing osteoclas-
tic resorption and total bone turnover, the administration of
BP, in the presence of bioavailable BMP2, has been
hypothesized to possibly lead to impaired bone healing.
The aim of the present study was to evaluate the effects
of ALN on the healing process of a critical-size defect,
filled with CaP ceramics, in the femora of osteoporotic rats
in the presence of BMP2 and L51P. The data suggest that




This study was approved by the local committee for animal
experimentation (Bern Committee for the Control of Ani-
mal Experimentation, Bern, Switzerland, permit number
BE67/16 toWH). Wistar Crl: WI (Han) rats (female, retired
breeders, 8–10 months old and weighing 285–580 g) were
purchased from Charles River (Sulzfeld, Germany). The
animals were housed in the Central Animal Facility of the
Medical Faculty, University of Bern, Switzerland, in com-
pliance with the Swiss Federal Government guidelines for
care and use of experimental animals. Animals were allo-
cated to one of three groups (sham, ovariectomized (OVX)/
vehicle and OVX/ALN) based on their bodyweight such
that the average weight of the animals was not statistically
different among the groups. For this purpose, the animals,
after equilibration in the facility and before OVX, were
divided into three groups (high, medium and low weight)
and the animals from each weight group were randomly
allocated to each experimental group using a Random
Number Generator for iPad. The experimental design and
the time course of the study are depicted in Figure 1.
Briefly, at t ¼ 0, animals were either OVX or sham-oper-
ated. ALN (OVX only) or vehicle (sham/OVX) treatment
was initiated 8 weeks after OVX and continued until sacri-
fice. A critical-size defect was applied in the left femur
5 weeks after the onset of vehicle/ALN treatment (13 weeks
post-OVX) and stabilized with a rigid osteosynthesis sys-
tem (RatFix™, RISystem AG, Davos, Switzerland). For all
surgical procedures, the rats were anaesthetized by subcu-
taneous injections (1 ml/kg body weight) of a 1:2 mixture
Figure 1. Time course/experimental design of ALN-treated osteoporotic femoral defect model. Thirteen weeks before the femoral
critical-size defect, animals were either OVX or sham-operated. VH or ALN (in OVX only) was administered twice a week s.c. 5 weeks
prior to insertion of the femoral defect until sacrifice. Mid-diaphysis femoral defects (6 mm) were stabilized with a PEEK plate with six
interlocking screws (RatFix™, RISystem), and a bTCP cylinder was placed within the defect. Samples were collected 16 weeks after
femoral surgery for histological analysis and microCT measurements. VH: vehicle; PEEK: polyether ether ketone; ALN: alendronate;
OVX: ovariectomized; bTCP: b-tricalcium phosphate; microCT: micro-computer tomography.
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of ketamine hydrochloride (33 mg/kg body weight; 100
mg/ml) and xylazine hydrochloride (13.3 mg/kg body
weight; 20 mg/ml). During surgery, the animals were
placed on a heating pad to prevent hypothermia. Group
sizes were n ¼ 6. Sixteen weeks after femoral surgery,
euthanization of animals was performed using CO2, fol-
lowed by cervical translocation, and samples were col-
lected for micro-computer tomography (microCT) and
histological analysis. In total, 12 experimental groups were
used, encompassing a total of 72 rats.
Ovariectomy
After shaving and disinfection, the ovaries were
approached through two 2.5 cm flank incisions at the
mid-dorsum. The skin was detached from the underly-
ing muscles before incising the muscles. The ovaries
were identified, clamped and removed (gently pulled
through the incisions and a haemostat was placed
between the oviduct and the ovaries). The oviducts
were ligated and a cut was made between the haemostat
and the ovaries. Haemostasis was controlled before
replacing the ligated oviducts in the abdomen. The mus-
cle layer was closed with absorbable sutures, and the
skin was sutured with non-absorbable thread. Sham-
operated animals underwent the same surgical proce-
dures, except for the ligation of the oviducts and the
removal of the ovaries.
BP treatment
ALN solution was prepared as previously described24 and
dissolved in 0.9% NaCl. ALN (1.61 mmol/kg body weight;
2 ml/kg bodyweight) or vehicle (0.9% NaCl solution; 2 ml/
kg body weight) was subcutaneously injected 8 weeks after
OVX twice weekly until sacrifice. After 8 weeks, bone mass
was significantly reduced in OVX animals as compared to
sham controls.
Loading of ceramic b-tricalcium phosphate cylinders
with peptides and release kinetics
Ceramic b-tricalcium phosphate (bTCP) cylinders (diam-
eter 5 mm, length 6 mm and porosity 75%) were used as
described previously21 and were generously provided by
the Robert Mathys Foundation (Bettlach, Switzerland). The
BMP2 and L51P proteins were expressed in Escherichia
coli and were kindly provided by Prof. W Sebald, Univer-
sity of Wu¨rzburg, Germany.19,25,26 For the measurement of
the in vitro release of L51P and BMP2 from the ceramics, 1
or 10 mg of BMP2 or L51P was dissolved in 25 ml of
deionized water and adsorbed onto bTCP carriers. After
24 h of drying at room temperature, the loaded ceramics
were incubated in 1.5 ml culture medium (alpha-minimum
essential medium, 10% foetal bovine serum and 1% peni-
cillin/streptomycin) for 16 days. The medium was changed
after 24 h, and after 2, 4, 8 and 16 days. The amounts of
BMP2 and L51P released into the culture medium were
quantified using an ELISA kit for the detection of BMP2
and L51P (Human BMP2 ELISA development kit, Pepro-
tech, Rocky Hill, Connecticut, USA).
Fixation of the critical-size femoral defect and
implantation of βTCP cylinders
For the loading of the bTCP implants to fill the critical-
size defects, BMP2 and L51P were dissolved in 25 ml
of deionized water and adsorbed to bTCP carriers
(Table 1). The loaded carriers were air-dried overnight
at room temperature and implanted into 6 mm critical-
size segmental diaphyseal bone defects in the rat femora
(five groups, n ¼ 6 per group), as recommended by the
manufacturer (https://vimeo.com/130984695). Thirteen
weeks after OVX and five weeks after the commence-
ment of the ALN treatment, the central part of the left
mid-diaphyseal femur (6 mm) was surgically removed.
After shaving and disinfection of the skin, a longitudinal
incision in line with the left femur was cut on the lateral
thigh. The interval between the vastus lateralis and the
biceps femoris was developed to expose the bone, the
gluteus superficialis tendon was detached from the tro-
chanter tertius and the RatFix™ System (RISystem AG,
Davos, Switzerland) was mounted onto the intact femora
using six interlocking screws. Subsequently, using two
Gigli saws, two osteotomies were created between the
two central screws, and the central mid-diaphyseal bone
fragment was collected for further analysis. Care was
taken not to harm the surrounding periosteum. Debris
was removed by rinsing the defect site with sterile phy-
siological saline solution. Subsequently, a bTCP
implant, which was stabilized with a non-absorbable
polypropylene thread, was inserted into the defect and
the wound was closed. After the animals recovered from
anaesthesia, analgesia was performed for 3 days, using
Temgesic (0.0075 mg/kg body weight; 0.3 mg/ml), and
full load bearing and unrestricted cage activity were
allowed. Movement or instability of the implants and
failure of the osteosynthesis were monitored using
high-resolution X-ray imaging immediately after sur-
gery. After 16 weeks, the implants, together with the
surrounding tissues, were harvested and analysed.
Table 1. BMP2 and L51P loading of bTCP carriers.
Experimental groups
I II III IV V
Unloaded 1 mg BMP2 10 mg BMP2 10 mg L51P 1 mg BMP2/
10 mg L51P
bTCP: b-tricalcium phosphate; BMP: bone morphogenetic protein.
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X-ray
After surgery, the integrity of the surgical site was docu-
mented using high-resolution radiography, applying the
following image acquisition parameters: 25 kV and 10 s
acquisition time (MX-20, Faxitron X-Ray Corporation,
Edimex, Le Plessis, France). No animals needed to be
excluded from the experiment post-operatively because of
incorrect defect localization and/or plate positioning.
Peripheral quantitative computed tomography
The effects of OVX on bone mass and structure were eval-
uated using in vivo peripheral quantitative computed tomo-
graphy (pQCT; XCT Research SA, Stratec Medizintechnik
GmbH, Birkenfeld, Germany) measurements at the left dis-
tal femur and proximal tibia, 7 weeks after OVX, using the
following parameters: voxel size, 70 mm; High Voltage, 50
kV; and acquisition time, 10 min. For pQCT analysis, ani-
mals were anaesthetized as described above.
Micro-computer tomography
The tissues for histological and microCT analysis were
fixed with 4% paraformaldehyde in Phosphate Buffered
Saline (PBS) for 24 h, and subsequently transferred to
70% ethanol. Polyether ether ketone (PEEK) plate and
Titanium screws remained in situ for these analyses. For
microCT analysis (MicroCT40, SCANCO Medical AG,
Bru¨ttisellen, Switzerland), the built-in software from
SCANCO was used (SCANCO Module 64-bit; V5.15).
The long axis of the femur was oriented orthogonally to
the axis of the X-ray beam. The X-ray tube was operated
at 70 kVp and 114 mA, and the integration time was set
at 200 ms. The measurements were performed perpendi-
cular to the longitudinal axis of the femora. Bone
growth was evaluated in the area between the two cen-
tral screws of the fixation systems. To distinguish
between soft and mineralized tissues, the tissue was
segmented into two tissue types based on their greyscale
(grey-level coded mineralization density), that is, <200
Hounsfield unit (HU) for soft tissues and >200 HU for
mineralized tissues (bTCP carrier, mineralized cartilagi-
nous callus, woven and lamellar bone).27 Cortical thick-
ness was measured using the SCANCO built-in
algorithm. The analysis was performed with a voxel size
of 8 mm.28
Histological analysis and histomorphometry
After microCT analysis, the tissues were embedded in
methyl methacrylate as described previously.29 Thereafter,
ground sections of approximately 200 mm were prepared
(Leica SP1600, Leica Microsystems, Glattbrugg, Switzer-
land). The sections were polished and stained with McNeal
tetrachrome.30,31 Microphotographs were taken using a
Nikon Eclipse E800 microscope (Nikon Inc., Egg,
Switzerland). Bone formation and implant turnover were
determined by the ImageJ trainable segmentation plugin;
Waikato Environment for Knowledge Analysis (WEKA)
automated segmentation histomorphometry32 on 4 serial
McNeal tetrachrome-stained ground sections per implant.
The sum of the surface area of bone and implant was deter-
mined for each animal (four sections/animal). The total
bone surface area and implant surface area per treatment
group were computed.
Uterus dry weight
Uteri were collected post-mortem, stored overnight at room
temperature, and the dry weight was measured 24 h after
collection.
Statistical analysis
The following statistical analyses were performed using
GraphPad Prism 7 for Windows (GraphPad Software,
San Diego, California, USA, www.graphpad.com).
Unpaired t-test was used for bodyweight and uterus dry
weight analysis; two-way analysis of variance
(ANOVA) with Tukey post hoc was applied to pQCT,
microCT and histomorphometry analysis. Mean values
with standard deviations are shown. Significant at p <
0.05. For multiple testing, padj < 0.05 was considered
significant.
Results
Release of BMP2 and L51P from bTCP ceramics
BMP2 and L51P were released in vitro with identical
kinetics over the course of 16 days, as determined by
ELISA (data not shown).
Bone loss in OVX rats and the effects of BP
The effect of OVX on bone mass was determined in vivo by
pQCT analysis in proximal tibiae and distal femora at time
of OVX and 7 weeks thereafter. Cortical and trabecular
densities did not vary between OVX and sham groups at
the time of surgery. After 7 weeks, both cortical and trabe-
cular densities were significantly decreased in OVX ani-
mals in measurements at four different tibial sites (tibia
position 1: 1122.4 + 49.4 mg/cm3 vs. 1022.6 + 42.3
mg/cm3, p < 0.0001; 248.2 + 60 mg/cm3 vs. 203 + 57.3
mg/cm3, p ¼ 0.0002; Figure 2).
To confirm the efficiency of OVX, uterine dry weight
was measured post-mortem. Uterine dry weight was
reduced by 40% in OVX animals as compared to that in
sham-operated animals. (sham vs.OVXþ vehicle, 248.4+
62.9 mg vs. 138.7+ 41.4 mg, p¼ 0.0001; sham vs.OVXþ
ALN, 248.4+ 62.9 mg vs. 143.2+ 37.3 mg, p ¼ 0.0001;
Online Supplemental Figure 1).
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Treatment with ALN leads to an increase in
cortical thickness
To assess the effects of ALN treatment in OVX animals,
cortical thickness was determined by microCT analysis of
the mid-diaphyseal fragments collected during the creation
of femoral critical-size defects (corresponding to 13 weeks
after OVX and 5 weeks after onset of the ALN treatment).
Administration of ALN resulted in a significant increase of
the cortical thickness as compared to that in vehicle treated
OVX animals (0.64+ 0.06 mm vs. 0.58+ 0.05 mm, p ¼
0.0066; Figure 3).
Bone formation is stimulated by BMP2 and implant
turnover is reduced by ALN
Sixteen weeks after implantation, no bone formation and
osseointegration of the CaP implant was observed in the
critical-size defects upon insertion of unloaded bTCP (con-
trol) cylinders irrespective of sham/OVX and vehicle/ALN
treatments (Figures 4(a), (f), (k) and 5(a)). Similarly, no
bone formation was found when the defects were filled
with 10 mg L51P-loaded bTCP cylinders, again indepen-
dently of the applied treatment protocols (sham, 1.55 +
0.39 mm2 (unloaded) and 1.84 + 0.31 mm2 (L51P), p ¼
0.9998; OVX/vehicle, 1.37 + 0.27 mm2 and 2.14 + 0.81
mm2, p ¼ 0.9942; OVX/ALN, 1.87+ 0.57 mm2 and 2.89
+ 2.14 mm2, p ¼ 0.9708; Figures 4(d), (i), (n) and 5(a)).
Some bone formation was detected in defects filled with
1 mg BMP2-loaded bTCP cylinders (Figure 4(b), (g), (l)),
but quantitative histomorphometry revealed no significant
increase in bone formation as compared to unloaded bTCP
cylinders, irrespective of sham/OVX and vehicle/ALN
treatments (sham, 1.55 + 0.39 mm2 vs. 3.12 + 2.62
mm2, padj ¼ 0.9272; OVX/vehicle, 1.37 + 0.27 mm2 vs.
4.25+ 2.82 mm2, p ¼ 0.6185; OVX þ ALN, 1.87+ 0.57
mm2 vs. 5.76 + 4.24 mm2, p ¼ 0.2954; Figure 5(a)).
Induction of bone formation was observed with bTCP
cylinders loaded either with 10 mg BMP2 (sham, 1.55 +
0.39 mm2 vs. 12.41 + 5.02 mm2, p ¼ 0.0003; OVX/vehi-
cle, 1.37+ 0.27 mm2 vs. 10.41+ 2.37 mm2, p ¼ 0.0004;
OVX/ALN, 1.87+ 0.57 mm2 vs. 14.49+ 4.06 mm2, p ¼
0.0001; Figures 4(c), (h), (m) and 5(a)) or 1 mg BMP2/10
mg L51P (sham, 1.55 + 0.39 mm2 vs. 9.86 + 4.51 mm2,
p ¼ 0.0031; OVX/ALN, 1.87 + 0.57 mm2 vs. 12.62 +
5.95 mm2, p ¼ 0.0001; Figures 4(e), (o) and 5(a)). In OVX
Figure 2. In vivo pQCT measurements of tibial trabecular and cortical densities. Densities of cortical and cancellous bone were
measured 7 weeks post-OVX by pQCT. (a) Trabecular density of the proximal tibiae. (b) Cortical density of the proximal tibiae.
Densities of both trabecular and cortical bones of OVX animals significantly decreased as compared to those of sham animals in four
virtual sections, measured 0.3 mm step from mid-joint (tibia 1–4). Two-way ANOVA with Tukey post hoc, OVX vs. sham for each time
point. *p < 0.05, ***p < 0.001, ****p < 0.0001, n ¼ 24. pQCT: peripheral quantitative computed tomography; OVX: ovariectomized;
ANOVA: analysis of variance.
Figure 3. Cortical thickness of femoral diaphysis. Cortical
thickness of the femoral mid-diaphysis collected during
femoral surgery was assessed by microCT. A significant
increase in the cortical thickness was observed in bones from
ALN-treated animals as compared to those from vehicle-
treated OVX rats. Kruskal–Wallis with Dunn’s post hoc test,
n ¼ 25–27. MicroCT: micro-computer tomography; ALN:
alendronate.
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animals receiving bTCP cylinders loaded with 1 mg
BMP2/10 mg L51P (Figure 4(j)), no significant increase
in bone formation was detected (1.37 + 0.27 mm2 vs.
5.81+ 2.84 mm2, p ¼ 0.1356). As previously observed,21
bone formation was associated with implant turnover in
sham-operated animals. An increased volume of residual
bTCP implant material remained in the defect site in ALN-
treated animals as compared to vehicle-treated animals
receiving bTCP implants with identical protein loads (10
mg BMP2 (OVX/vehicle vs. OVX/ALN, 1.99 + 0.52 mm2
vs. 5.48 + 1.62 mm2, padj < 0.0001; Figures 4(m) and
5(b)); 1 mg BMP2/10 mg L51P (OVX/vehicle vs. OVX/
ALN, 1.39 + 0.72 mm2 vs. 4.33 + 1.20 mm2, padj <
0.0001; Figures 4(o) and 5(b)). Although minimal extra-
implant/peripheral bone formation was observed in
vehicle-treated animals whose defects were filled with
10 mg BMP2 and 1 mg BMP2/10 mg L51P loaded bTCP
cylinders (Figure 4(c), (e), (h), (J)), respectively, extensive
peripheral bone formation was observed in defects from
ALN-treated animals (Figure 4(m), 4(o)) with identical
bTCP loading conditions. After 16 weeks, microCT ren-
derings of the defect sites revealed that bTCP cylinders
loaded with 10 mg BMP2 or 1 mg BMP2/10 mg L51P
formed an interface with the host bone. In defects from
vehicle-treated animals in which implants were loaded with
10 mg BMP2 or 1 mg BMP2/10 mg L51P, bone formation
Figure 4.Methyl metacrylate histologies of bTCP ceramics in femoral critical-size defects. Cross sections of bTCP cylinders implanted
in critical-size femoral defects collected 16 weeks after surgery and stained with McNeal tetrachrome are shown. Implants from sham
animals (a–e); implants from vehicle-treated OVX rats (f–j); implants from OVX animals treated with ALN (k–o). No bone growth was
observed in animals that received empty control ceramics (a, f, k) or ceramics loaded with 10 mg L51P (d, i, n) irrespective of sham/OVX
and ALN/vehicle treatments. Little and irregular bone formation was observed in ceramics loaded with 1 mg BMP2 (b, g, l) irrespective
of sham/OVX and ALN/vehicle treatments. Bone formation was observed in animals with implants loaded with 10 mg BMP2 (c, h, m) or
10 mg L51P/1 mg BMP2 (e, j, o) irrespective of sham/OVX and ALN/vehicle treatments. Increased volumes of residual ceramics were
observed in ALN-treated animals with bTCP implants loaded with 10 mg BMP2 (m) and 10 mg L51P/1 mg BMP2 (o) compared to vehicle-
treated animals with bTCP implants loaded with 10 mg BMP2 (c, h) or 10 mg L51P/1 mg BMP2 (e, j). Bars represent 1 mm. ALN:
alendronate; OVX: ovariectomized; bTCP: b-tricalcium phosphate; BMP: bone morphogenetic protein.
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occurred from either the distal or proximal end of the defect
and did not fill the entire implant. In contrast, defects in
ALN-treated animals filled with bTCP cylinders loaded
with 10 mg BMP2 or 1 mg BMP2/10 mg L51P were char-
acterized by a bone continuum throughout the entire bTCP
implant (Figure 6). MicroCT analysis of serial cross-
sections along the longitudinal axis of the defects suggested
that the surface area of bone was decreasing from the bone–
implant interface towards the centre of the implant. Evalua-
tion of cross-sectional 2-D microCT images confirmed the
reduction of the bone surface area from the bone–implant
interface towards the centre of the defect (Figure 7).
Discussion
BP are the most frequently prescribed drugs to preserve
bone mass and microarchitecture. Treatment with BP and
the consequential maintenance of the bone substance
results in a decrease in the risk to sustain wrist, vertebral
and hip fractures in patients suffering from osteoporosis.4, 7, 9
Because prolonged treatment with BP causes bone turn-
over to slow down, and because the concept of a drug
holiday during BP treatment is controversially discussed,33
it is an open question whether bone repair is impaired by
concurring treatment with BP in osteoporotic patients. The
present study aimed to answer several aspects of repair of a
critical-size femoral defect, with bTCP as a bone filler, in
estrogen deficient osteoporotic rats treated with BP such as
(i) the preservation of the previously described synergistic
effect of BMP2 and L51P on bone healing, (ii) the effects
of BP treatment on bone repair and remodelling of the
defect site and (iii) the turnover of a bTCP implant under
conditions of blocked osteoclast activity. The data demon-
strate that, as was previously shown,21 L51P causes an
increase in the effects of BMP2 on bone formation in
sham-operated animals, leading to an increase in bone vol-
ume at the defect sites 16 weeks post-implantation com-
pared to animals with implants loaded with 1 mg BMP only
or unloaded controls. L51P alone, at 10 mg, did not induce
any detectable formation of bone. In animals treated with
ALN, bone formation was induced in defects filled with
cylinders loaded with 10 mg BMP2 and with 1 mg BMP2/10
mg L51P, respectively.
One common feature observed in vehicle-treated control
animals, which received implants loaded with either 10 mg
BMP2 or 1 mg BMP2/10 mg L51P, is the presence of intact
bTCP ceramic material surrounding the newly formed
bone in a ring-like structure. Since the diameter of the
bTCP implants exceeds the diameter of the femoral dia-
physis, we hypothesized that with the present experimental
setup, bone formation is constrained to a volume similar to
the original bone volume. It would be of particular interest
to investigate whether the remaining implant will be filled
with bone and remodelled or removed without additional
bone formation, if the period allowed for repair is
prolonged.
Compared to the newly formed bone in the critical-size
defects from control animals, bone formation in animals
receiving both ALN and 10 mg BMP2 or 10 mg L51P/
1 mg BMP2 exceeded the original bone volume and the
Figure 5. Bone formation and bTCP turnover. Bone formation and turnover of bTCP ceramics were quantified by automated
histomorphometry. The surface areas of bone and implant were computed withWEKA (automated segmentation) on four sections per
animal. (a) Total bone surface area in treatment groups. Bone formation was significantly increased with 10 mg BMP2, irrespective of
sham/OVX and vehicle/ALN. A significant increase in bone formation was observed in sham/ALN and OVX/ALN animals with ceramics
loaded with 1 mg BMP2/10 mg L51P. (b) Total ceramics surface areas in treatment groups. Residual surface of bTCP ceramics was
significantly larger in ALN-treated animals whose defects were filled with implants coated with either 10 mg BMP2 or 1 mg BMP2/10 mg
L51P than in sham and OVX control animals. Two-way ANOVA with Tukey post hoc, compared to treatment protocol (OVX/sham, VH/
ALN) matched unloaded bTCP cylinder. *Significant at p < 0.05, ***significant at p < 0.001, ****significant at p < 0.0001, n ¼ 3–6.
WEKA: Waikato Environment for Knowledge Analysis; ALN: alendronate; OVX: ovariectomized; bTCP: b-tricalcium phosphate; BMP:
bone morphogenetic protein.
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perimeter of the implant. Besides the excessive bone
formation, implant turnover was greatly reduced in ani-
mals treated with ALN. Quantitative evaluation of the
remaining bTCP ceramics revealed that the volume of
bTCP in ALN-treated animals was doubled when com-
pared with the volume of bTCP in vehicle-treated ani-
mals upon loading of the ceramics with 10 mg BMP2
and 10 mg L51P/1 mg BMP2, respectively. As reported
previously, bone formation and growth into the porous
bTCP implants are prerequisites for the turnover of the
ceramics. The inhibition of osteoclastic bone resorption
by ALN, however, decreased the dissolution of bTCP
ceramics, demonstrating the implant turnover to depend
on osteoclast activity and not on the ceramic’s chemical
solubility.
In physiological bone remodelling, coupling of osteo-
clast and osteoblast activities is crucial for the maintenance
of mass and structure of bone. In the presence of supraphy-
siological levels of BMP2, bone formation and resorption
are uncoupled. As a consequence, in our study, bone
formation induced by BMP2 was not affected in animals
treated with ALN, despite the block of resorption. When
animals are treated with ALN, irrespective of BMP2 levels,
bone remodelling will not take place and therefore primary
woven bone will not be replaced by secondary, mechani-
cally more competent lamellar bone.
The present study provided evidence on two crucial
aspects relevant to reconstructive orthopaedic surgery.
Firstly, it corroborated the usefulness of the strategy to
block endogenous BMP antagonists to improve the bioef-
ficacy of exogenously added BMP. Secondly, it demon-
strated the necessity for functional cellular resorption for
the removal of bTCP ceramics from a repair site. There are,
however, also limitations of the present model. The dura-
tion of the study was too short for a complete removal of
the bTCP biomaterial. Furthermore, no biomechanical test-
ing of the partially or fully healed defects could be per-
formed. Despite these limitations, however, the data
suggest that in patients treated with BP, healing of bTCP-
filled bone defect may be impaired because of the failure to
Figure 6. MicroCT 3D renderings of femoral defects. Representative renderings from critical-size femoral defects filled with cylinders
loaded with 10 mg BMP2 are depicted for (a) sham, (b) OVX and (c) OVX/ALN. Renderings from defects filled with ceramics loaded with
1 mg BMP2/10 mg L51P are shown in panels (d) sham, (e) OVX and (f) OVX/ALN. Bone formation occurs preferentially at the proximal
and distal ends of the implants in sham and OVX control animals irrespective of BMP2 and BMP2/L51P loading of the implants (a, b, d, e).
In animals treated with ALN, bone formed from both the distal and proximal ends of the defects, the newly formed bone bridging the
defect irrespective of BMP2 and BMP2/L51P loading of the implants (c, f). ALN: alendronate; OVX: ovariectomized; BMP: bone
morphogenetic protein; microCT: micro-computer tomography.
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remove the implant material and its replacement by authen-
tic bone.
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